|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
Little is known about how oncologists' adopt new treatments for breast cancer. This study investigated influences on oncologists' adoption of paclitaxel as adjuvant chemotherapy for early-stage breast cancer, 9 months after presentation of phase III data suggesting improved disease-free and overall survival when paclitaxel was added to doxorubicin and cyclophosphamide for such patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
954-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11181657-Breast Neoplasms,
pubmed-meshheading:11181657-Chemotherapy, Adjuvant,
pubmed-meshheading:11181657-Clinical Trials, Phase III as Topic,
pubmed-meshheading:11181657-Female,
pubmed-meshheading:11181657-Humans,
pubmed-meshheading:11181657-Models, Psychological,
pubmed-meshheading:11181657-Paclitaxel,
pubmed-meshheading:11181657-Physician's Practice Patterns
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Influences on oncologists' adoption of new agents in adjuvant chemotherapy of breast cancer.
|
|
pubmed:affiliation |
Wellmark Foundation, Des Moines, Iowa, USA.
|
|
pubmed:publicationType |
Journal Article
|
